Source: Lieyun Network
On March 11, Bochuang Biotech announced the completion of a multi-million-yuan Pre-A+ round of financing, exclusively and strategically invested by Sunland Capital, a professional investment institution in the healthcare sector.
This is the fourth round of financing Bochuang Biotech has received within three years.
According to Tianyancha, Bochuang Biotech was founded in June 2022 as a high-tech leading enterprise integrating research, production, and sales.
Relying on the technology of Academician Liu Changsheng's team, the company conducts in-depth cooperation with well-known institutions such as East China University of Science and Technology and Shanghai University, focusing on the innovative development of high-end collagen raw materials and downstream medical device products. It has now built an integrated R&D and production platform that includes raw material research and development, raw material production, product customization, concept verification, manufacturing processing, and product testing. The platform is equipped with more than a hundred pieces of equipment for extraction, synthesis, processing, and testing, and features comprehensive R&D laboratories, cell evaluation laboratories, animal evaluation laboratories, and a Grade 10,000 clean GMP workshop.
The company has now applied for multiple patents and formed a relatively complete technical barrier. Bochuang Biotech will leverage its advantages in large-molecule collagen extraction, electrochemical controllable assembly technology, and talented personnel. Using electrochemical controllable deposition as the primary technical platform and guided by clinical needs, the company will develop a series of innovative products for key departments such as ophthalmology and stomatology, promoting the upgrading of collagen repair and tissue regeneration products.
Currently, Bochuang Biotech is deeply engaged in the field of innovative implantable biomedical materials, building a moat for enterprise development with original core technologies.
Relying on the EDP original technology platform, Bochuang Biotech has achieved key advancements in multiple technical breakthroughs and product implementations in core fields of high-end implantable devices such as ophthalmology, dentistry, and skin repair, continuously delivering product outcomes that combine high clinical value with technological innovation.
Bochuang Biotech's self-developed collagen artificial corneal stromal patch (E-Col) has officially launched clinical enrollment research at the Eye, Ear, Nose, and Throat Hospital of Fudan University. This product, optimized with molecular-level structural precision, boasts a light transmittance exceeding 95%. Its tensile strength and elastic modulus perfectly meet clinical implantation standards, effectively reducing the risks of immune rejection and neovascularization. It provides an excellent solution for the localization of high-end ophthalmic implants in China. The company’s oral bone tissue-guiding membrane has completed key technology validation and is now in the countdown phase to initiate clinical application submission, marking a significant innovative achievement in the field of high-end dental implant materials in China.
Dr. Tan Haoqi, founder of Bochuang Biotech, stated: "The successful completion of this round of financing is an important boost in the company’s development process. The subsequent funds will be primarily invested in three core areas: clinical efforts for core products, iterative upgrades of the EDP technology platform, and industrial capacity layout. This will further consolidate the company’s leading position in domestically produced high-end implantable biomaterials in ophthalmology and dental fields. In the future, Bochuang Biotech will continue to focus on unmet clinical needs, with technological innovation as the core driving force, accelerating the commercialization of products under research. At the same time, we will continuously unlock more application scenarios for high-end implantable medical devices such as trauma repair, promoting the import substitution and industrial upgrading of high-end implantable biomedical devices through independent innovation. Our goal is to make China-produced advanced medical technology benefit a wide range of patients and contribute professional strength to advancing China’s high-end implantable biomedical materials industry towards a new journey of high-quality development."